Document is current
Any future updates will be listed below
-
Authors
Malvisi, Lucio https://orcid.org/0000-0001-6551-5038
Taddei, Laura
Yarraguntla, Aparna
Wilkinson, Tom M. A.
Arora, Ashwani Kumar
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01360398 at ClinicalTrials.govDocuments that mention this clinical trial
Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints
https://doi.org/10.1186/s12931-021-01653-8
Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study
https://doi.org/10.1136/bmjopen-2013-004546
Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples
https://doi.org/10.1186/s12931-023-02525-z
A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD
https://doi.org/10.1136/thoraxjnl-2016-209023
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations
https://doi.org/10.1136/thoraxjnl-2017-210408
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
- License Information
-
More Information
Article History
Received: 20 August 2020
Accepted: 7 February 2021
First Online: 24 February 2021
Ethics approval and consent to participate
: AERIS was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, and was approved by the Southampton and South West Hampshire Research Ethics Committee (Research Ethics Committee reference number: 11/H0502/9). All subjects provided written informed consent.
: Not applicable.
: LM, LT, and AKA are employees of the GSK group of companies. AY is a consultant of ICON for the GSK group of companies. LT and AKA hold shares in the GSK group of companies and AKA has a patent PCT/EP2018/071860 – Methods of boosting immune responses – pending to the GSK group of companies. TMAW has received grants from the GSK group of companies during the conduct of this study. TMAW has also received grants from AstraZeneca, Synairgen, and MyMHealth and fees, reimbursement for travel and meeting attendance from Boehringer Ingelheim, Chiesi, and AstraZeneca, outside of the submitted work. In addition, TMAW has a patent 2018 US Patent 62/479562 – Immunogenic Composition, Use and Methods of Treatment – A novel vaccine to prevent exacerbations of COPD pending to the GSK group of companies. TMAW is the Founder and Director of MyMHealth Ltd. All authors declare having no other non-financial relationships and activities.
